Drug Type Small molecule drug |
Synonyms AFN 1252, AFN-12520000, API 1252 + [3] |
Target |
Mechanism MECR inhibitors(Enoyl-acyl-carrier protein reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H21N3O3 |
InChIKeyQXTWSUQCXCWEHF-JXMROGBWSA-N |
CAS Registry620175-39-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Abscess | Phase 2 | US | 01 Feb 2012 | |
Abscess | Phase 2 | CA | 01 Feb 2012 | |
Burn infections | Phase 2 | US | 01 Feb 2012 | |
Burn infections | Phase 2 | CA | 01 Feb 2012 | |
Cellulitis | Phase 2 | US | 01 Feb 2012 | |
Cellulitis | Phase 2 | CA | 01 Feb 2012 | |
Skin Diseases, Bacterial | Phase 2 | US | 01 Feb 2012 | |
Skin Diseases, Bacterial | Phase 2 | CA | 01 Feb 2012 | |
Wound Infection | Phase 2 | US | 01 Feb 2012 | |
Wound Infection | Phase 2 | CA | 01 Feb 2012 |
Phase 2 | 103 | dcxmvitdoi(qbodvmxefx) = headache (26.2%) and nausea (21.4%) hvbvmhjyar (lmqmtbtgtl ) | Positive | 28 Dec 2015 |